@ProfRAScolyer@SydneyLHD@Sydney_Uni Best of luck Prof. for what it worth I just had a scan 6 months after WBRT and it’s showed an across the board 66% reduction in scope and size of all Mets. Your story has been an inspiration for me.
@motherofswans@ProfRAScolyer It’s a wonderful story of success so far, but one thing is guaranteed, the more time goes on the more people effected by this horrendous disease will be asking, ‘why can’t I access that treatment?’
@exosome @ProfRScolyerMIA Fellow melanoma prof Georgina long, joint Australian of the year pivotal in developing experimental protocol based on applying melanoma/immunotherapy treatments to GBM. Still early days but latest scan days ago, no evidence of disease. Worth reading through his story on X feed.
@exosome @ProfRScolyerMIA Remarkable, ongoing story of 2024 Australian of the year and his recent journey with a GBM diagnosis. Chose to forego SOC treatment in favor of an experimental protocol involving surgery, some sort of customised vaccine and immunotherapy. Latest up date days ago on X, still NED.
@lieulieubell I wish they would spend the money on research instead of awareness. We are aware!!! Some breast cancer foundations spend 5% on research but have a tagline, “Help is find a cure.” They cure Stage IV, they cure everyone. Duh!
This immune cell soldier (yellow) fights a highly aggressive cancer cell (magenta).
https://t.co/KnYP9ruvOT
The cancer cell is a tough opponent to face and it takes multiple punches to knock it out. The cancer cell contains a sensor that lights up when it is being punched by a T-cell soldier.
This model is used to study why the immune system fails to kill cancer cells in patients. With these insights, researchers can develop new treatments to strengthen the immune response against cancer.
[📹 Slaats Jeroen]
TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors. Pleasure expedite for Er+Her2- metastatic breast cancer. $RNAZ #MBC#bcsm https://t.co/P0BBNLKatB